| pubmed-article:184377 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C0009002 | lld:lifeskim |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C0020476 | lld:lifeskim |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:184377 | lifeskim:mentions | umls-concept:C0605323 | lld:lifeskim |
| pubmed-article:184377 | pubmed:issue | 36 | lld:pubmed |
| pubmed-article:184377 | pubmed:dateCreated | 1976-11-21 | lld:pubmed |
| pubmed-article:184377 | pubmed:abstractText | The effect of essential phospholipids in combination with Clofibrate (N 041) was compared with that of Clofibrate alone in a double blind study in 96 patients with hypertriglyceridemia and/or hypercholesterolemia. The serum triglycerides fell more markedly with N 041 than with Clofibrate therapy alone. The greater cholesterol-lowering effect of N 041 was significant after treatment lasting 3 weeks and just failed to reach the 5% significance level after 6 weeks. Both preparations were well tolerated. | lld:pubmed |
| pubmed-article:184377 | pubmed:language | ger | lld:pubmed |
| pubmed-article:184377 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:184377 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:184377 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:184377 | pubmed:issn | 0341-3098 | lld:pubmed |
| pubmed-article:184377 | pubmed:author | pubmed-author:GaertnerUU | lld:pubmed |
| pubmed-article:184377 | pubmed:author | pubmed-author:JohannesK JKJ | lld:pubmed |
| pubmed-article:184377 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:184377 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:184377 | pubmed:volume | 118 | lld:pubmed |
| pubmed-article:184377 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:184377 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:184377 | pubmed:pagination | 1127-30 | lld:pubmed |
| pubmed-article:184377 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-H... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-A... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-C... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-P... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-G... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-F... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-D... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-M... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-A... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-H... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-H... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-T... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-M... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-C... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-C... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-L... | lld:pubmed |
| pubmed-article:184377 | pubmed:meshHeading | pubmed-meshheading:184377-L... | lld:pubmed |
| pubmed-article:184377 | pubmed:year | 1976 | lld:pubmed |
| pubmed-article:184377 | pubmed:articleTitle | [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate]. | lld:pubmed |
| pubmed-article:184377 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:184377 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:184377 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:184377 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
